PPARG and glioblastoma: From the finding of decreased cell viability and stemness of MES GSCs upon PPARγ activation, a therapeutic strategy recovering receptor expression would be considered to prevent cellular plasticity of PN into the MES GSC subtype, which potentially attenuates intratumoral GBM heterogeneity.